PMID- 35211549
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220226
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 10
IP  - 4
DP  - 2022 Feb 6
TI  - Continuous intravenous infusion of recombinant human endostatin using infusion 
      pump plus chemotherapy in non-small cell lung cancer.
PG  - 1164-1171
LID - 10.12998/wjcc.v10.i4.1164 [doi]
AB  - BACKGROUND: Lung cancer is one of the deadliest cancers in the world with the 
      highest incidence and mortality rate among all cancers. Non-small cell lung 
      cancer (NSCLC) accounts for approximately 80% of primary lung cancer. However, 
      efficacy and safety of the current regimens for NSCLC is unsatisfactory. 
      Therefore, there has been an increasing urgency for development of potential 
      therapeutic therapies for NSCLC. AIM: To investigate the therapeutic outcomes and 
      safety of continuous intravenous infusion of recombinant human endostatin 
      (Rh-endostain) using an infusion pump in retreated advanced NSCLC. METHODS: 
      Patients with retreated advanced NSCLC who were admitted to Zhejiang Provincial 
      People's Hospital from October 2017 to April 2019 were recruited. These patients 
      received continuous intravenous infusion of Rh-endostain using an infusion pump. 
      Objective response rate (ORR), clinical benefit rate (CBR), median 
      progression-free survival (mPFS), and incidences of adverse events (AEs) were 
      analyzed after treatment. RESULTS: A total of 45 patients with retreated advanced 
      NSCLC were included, and all of them were evaluated. In these patients, ORR was 
      22.2%, CBR was 84.4%, and mPFS was 5.3 mo. The following AEs were observed, 
      decreased hemoglobin (34 cases, 75.6%), nausea/vomiting (32 cases, 71.1%), 
      elevated transaminase (24 cases, 53.3%), leukopenia (16 cases, 35.6%), 
      thrombocytopenia (14 cases, 31.1%), and constipation (1 case, 3.4%). None of the 
      patients had leukopenia, nausea /vomiting, and constipation of grade III and 
      above. CONCLUSION: The patients showed improved adherence to 5-d continuous 
      intravenous infusion of Rh-endostain using an infusion pump. Favorable efficacy 
      and safety of this treatment regimen were achieved in retreated advanced NSCLC.
CI  - (c)The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Qin, Zhi-Quan
AU  - Qin ZQ
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
FAU - Yang, Si-Fu
AU  - Yang SF
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
FAU - Chen, Yun
AU  - Chen Y
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
FAU - Hong, Chao-Jin
AU  - Hong CJ
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
FAU - Zhao, Tong-Wei
AU  - Zhao TW
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
FAU - Yuan, Guo-Rong
AU  - Yuan GR
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
FAU - Yang, Liu
AU  - Yang L
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
FAU - Gao, Liang
AU  - Gao L
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
FAU - Wang, Xiao
AU  - Wang X
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
FAU - Lu, Li-Qin
AU  - Lu LQ
AD  - Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's 
      Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China. 
      llq199@outlook.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC8855203
OTO - NOTNLM
OT  - Chemotherapy
OT  - Continuous intravenous infusion
OT  - Non-small cell lung cancer
OT  - Recombinant human endostatin
COIS- Conflict-of-interest statement: The authors declared no conflicts of interest for 
      this manuscript.
EDAT- 2022/02/26 06:00
MHDA- 2022/02/26 06:01
PMCR- 2022/02/06
CRDT- 2022/02/25 05:39
PHST- 2021/09/15 00:00 [received]
PHST- 2021/10/27 00:00 [revised]
PHST- 2021/12/22 00:00 [accepted]
PHST- 2022/02/25 05:39 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/02/26 06:01 [medline]
PHST- 2022/02/06 00:00 [pmc-release]
AID - 10.12998/wjcc.v10.i4.1164 [doi]
PST - ppublish
SO  - World J Clin Cases. 2022 Feb 6;10(4):1164-1171. doi: 10.12998/wjcc.v10.i4.1164.